Evidence map›Paper›PMID 33930043›Full record

ArticlePloS one2021

Facile production of chlorophyllides using recombinant CrCLH1 and their cytotoxicity towards multidrug resistant breast cancer cell lines.

Yi-Ping Hsiang, Yi-Ting Wang, Keng-Shiang Huang, Ting-Yu Huang, Mi-Hsueh Tai, Yu-Mei Lin, Chih-Hui Yang, Jei-Fu Shaw

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yi-Ping HsiangInstitute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung, Taiwan.
Yi-Ting WangDepartment of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan.
Keng-Shiang HuangThe School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.
Ting-Yu HuangDepartment of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan.
Mi-Hsueh TaiDepartment of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan.
Yu-Mei LinDepartment of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan.
Chih-Hui YangDepartment of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan.
Jei-Fu ShawDepartment of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan.ORCID 0000-0001-7493-9254
I-Shou University · TWE-Da Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purity of chlorophylls plays one of the key role for the production of chlorophyllides. We have designed a facile method for chlorophyll purification by twice solvent extraction. Twice extraction causes the loss of chlorophylls, but the purity of total chlorophylls can be enhanced 182%. Then, the purified chlorophylls can be converted to relatively pure chlorophyllides facilely. The results show that higher purity of chlorophyllides could be obtained when purified chlorophylls (ethanol-hexane extract) was used as starting materials than that of crude chlorophylls (ethanol-only extract). In biocompatibility test, the results showed that the prepared chlorophyllides can be applied as biomaterials. When the prepared chlorophyllides were applied to anticancer tests, they were active both in MCF7 and MDA-MB-231 (multidrug resistant breast cancer cells) cell lines. In addition, the results suggested that the prepared chlorophyllides could be a potential candidate of combination therapy with doxorubicin to breast cancers.

Indexed as

Breast NeoplasmsCell ProliferationChlorophyllChlorophyllidesDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleHumansMCF-7 CellsT-Lymphocytes, CytotoxicChlorophyllChlorophyllidesDoxorubicin

Identifiers

PMID33930043
PMCPMC8087012
OpenAlexW3159245535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.